抗PD_1_PD_L1单抗治疗肺癌临床研究进展_黄志煜.pdfVIP

706 · · 中国肺癌杂志2 0 1 5 年 1 1月第 1 8卷第 1 1期 Chin J Lung Cancer, November 2015, Vol.18, No.11 DOI: 10.3779/j.issn.1009-3419.2015.11.09 · 综 述 · 抗PD-1/PD-L1单抗治疗肺癌临床研究进展 黄志煜 李晖 综述 范云 审校 1 programmed death-1, PD-1 /PD-1 PD-1 ligand, PD-L1) 【 】近期，抗程序性死亡分子 （ ） 配体（ 单抗在晚期非 摘要 小细胞肺癌的治疗中纷纷取得了突破性进展，相关研究迅速覆盖到肺癌的其他领域，如小细胞肺癌、局部晚期非小 细胞肺癌；并且开始尝试与现有治疗手段的各种组合，如联合化疗、靶向药物及放疗等。但是，仍有许多问题有待 解决，如寻找理想的预测疗效的生物标记物、探索不同的联合治疗模式、明确原发及继发耐药的机制等等。随着这 些问题的相继解决，抗PD-1/PD-L1单抗在肺癌的治疗中将会有更加广阔的应用空间。 【关键词 】 免疫检验点；PD-1/PD-L1 ；单克隆抗体；肺肿瘤 Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer Zhiyu HUANG, Hui LI, Yun FAN Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China Corresponding author: Yun FAN, E-mail: Abstract Recently, the immune checkpoint inhibitors which target programmed death-1 (PD-1)/PD-1 ligand 【 】 (PD-L1) have made a breakthrough in the treatment of advanced non-small cell lung cancer. Researches on immune check- point inhibitors have been rapidly implemented in various types of lung cancer, such as small cell lung cancer and locally ad- vanced non-small cell lung cancer. These inhibitors have been applied in combination with other treatment strategies, including chemotherapy, targeting therapy and radiotherapy. However, there are still many problems to be solved, such as searching for ideal biomarkers, exploring different combination treatment models, and iden